Blog
RSS FeedPosted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 06 May 2021
ICER to assess treatment for severe asthma
6 May 2021 - Report will be subject of Midwest CEPAC meeting in November 2021; draft scoping document open to ...
Posted by Michael Wonder on 05 May 2021
ICER releases draft evidence report on aducanumab for Alzheimer’s disease
5 May 2021 - Given the risk of side effects and the uncertainty of benefit, ICER assigns a draft rating of ...
Posted by Michael Wonder on 29 Apr 2021
ISPOR launches HEOR solutions centre
27 April 2021 - New resource offers easy access to HEOR expertise from leading companies in the field. ...
Posted by Michael Wonder on 26 Apr 2021
ICER publishes white paper evaluating policy options to strengthen FDA’s accelerated approval pathway for prescription drugs
26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...
Posted by Michael Wonder on 16 Apr 2021
ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
Posted by Michael Wonder on 13 Apr 2021
New recommendations on the critical appraisal of systematic reviews with cost and cost effectiveness outcomes
13 April 2021 - ISPOR announced today the publication of new guidance on how to evaluate the quality and risk ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 12 Apr 2021
ICER publishes research protocol for assessing the unsupported price increases on prescription drugs that occurred in 2020
12 April 2021 - Final assessment to be published on 16 November; through 10 May, ICER is accepting public Input ...
Posted by Michael Wonder on 12 Apr 2021
ICER to use Aetion observational RWE to update value assessment of treatments for hereditary angioedema
12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...
Posted by Michael Wonder on 08 Apr 2021
ICER to assess treatment for hypertrophic cardiomyopathy
8 April 2021 - Report will be subject of CTAF meeting in October 2021; draft scoping document open to public comment ...
Posted by Michael Wonder on 05 Apr 2021
ICER publishes evidence report on therapies for multiple myeloma
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
Posted by Michael Wonder on 17 Mar 2021
ICER analyses are flawed, undervalue life saving medicines, and are biased toward price controls, finds new PRI brief
17 March 2021 - A commonly-used analysis to determine a medicine's value is based on flawed methodologies that would diminish ...
Posted by Michael Wonder on 15 Mar 2021
Aurinia announces positive cost effectiveness assessment of Lupkynis (voclosporin) in latest ICER draft evidence report
15 March 2021 -Aurinia Pharmaceuticals today announced a favorable assessment regarding the cost-effectiveness and value of Lupkynis (voclosporin), based on ...
Posted by Michael Wonder on 15 Mar 2021
ICER to assess treatments for myasthenia gravis
15 March 2021 - Report will be subject of New England CEPAC meeting in September 2021; draft scoping document open ...